Ribometrix @Ribometrix

Ribometrix is a biotechnology company developing small molecule therapeutics that modulate RNA biology to treat human diseases. ribometrix.com Durham, NC Joined February 2017

Tweets

39
Followers

337
Following

13
Likes

13

Ribometrix @Ribometrix

8 months ago

Ribometrix Strengthens Leadership, Appoints William S. Marshall, Ph.D., as Chief Executive Officer and Katie Warner, Ph.D., as Chief Scientific Officer globenewswire.com/news-release/2…

0 0 0 48 0

New preclinical data presented at #ESMO24 support the potential of RBX-6610 as a potential treatment for NSCLC with KRAS mutations and reinforce its promise in multiple tumor types. Read more in our press release: ribometrix.com/news/ribometri…

0 0 1 84 1

Ribometrix @Ribometrix

a year ago

Proud to be sharing new data from our eIF4E program @myESMO Sep 15. We’ll have new efficacy data, incl. re-sensitization of tumors to the standard-of-care – so crucial in non-small cell lung cancer. #nsclc #esmo24 #rnatherapeutics More: businesswire.com/news/home/2024…

0 0 0 57 0

Ribometrix @Ribometrix

a year ago

Today at #AACR24: new data across our portfolio, incl. POC of our small molecules to directly target c-MYC #RNA & reduce associated protein levels; and preclinical anti-tumor activity of our lead eIF4E preclinical candidate: ribometrix.com/news/ribometri…

0 0 0 105 0

Ribometrix @Ribometrix

2 years ago

Ribometrix will share new preclinical data at the 2024 #AACR Annual Meeting for our pioneering #RNA-modulating small molecule programs targeting elF4E and c-MYC. Learn more about our progress: ribometrix.com/?p=1406

0 1 2 179 3

Ribometrix @Ribometrix

2 years ago

Today we are presenting new preclinical data supporting the potential of our eIF4E inhibitors in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium (SABCS). More on our #SABCS23 data: ribometrix.com/news/ribometri…

0 0 1 160 0

Ribometrix @Ribometrix

2 years ago

Don’t miss our presentation of new preclinical data for our eIF4E inhibitor program at #SABCS23 in December. Data will show its potential in ER+ breast cancer, adding to our exciting early results in melanoma presented earlier this month. Learn more: bit.ly/3sZvVby

0 0 0 108 0

Ribometrix @Ribometrix

2 years ago

Today we present preclinical data at the 2023 #SMRCONGRESS for our lead program targeting #RNA binding protein and regulator of oncogene translation, eIF4E. We’re excited to be advancing a set of small molecule eIF4E inhibitors toward IND-enabling studies: ribometrix.com/news/ribometri…

0 1 3 248 1

Ribometrix @Ribometrix

4 years ago

We were honored to win a 2021 Life Sciences Award yesterday and we congratulate all of the other winners this year! We're proud to be part of such a thriving #TBJlifesci community.

Triangle Business Journal @TriangleBIZJrnl

4 years ago

We were honored to win a 2021 Life Sciences Award yesterday and we congratulate all of the other winners this year! We're proud to be part of such a thriving #TBJlifesci community.

0 0 1 0 0

0 0 0 0 0

Pairwise @PairwisePL

4 years ago

We’re honored to be named a 2021 @TriangleBIZJrnl #TBJlifesci Award winner! We believe in building a healthier world through better fruits and vegetables and are proud to call North Carolina’s intersection of technology and agriculture, Research Triangle Park, home.

0 2 6 0 0

Download Image

Ribometrix @Ribometrix

4 years ago

We're very proud to announce that we won Best Early-Stage Product Development Company at the @TriangleBIZJrnl 2021 Life Sciences Awards. Congratulations to our amazing team! #TBJlifesci Read more: bwnews.pr/2SeGnsF

0 2 3 0 0

Ribometrix @Ribometrix

5 years ago

Thanks @ArrakisTx, @Roche and @genentech - we're excited to be creating a new generation of small molecule #RNA therapies with a superb class of partners and peers.

Arrakis Therapeutics @ArrakisTx

5 years ago

Thanks @ArrakisTx, @Roche and @genentech - we're excited to be creating a new generation of small molecule #RNA therapies with a superb class of partners and peers.

0 2 21 0 2

0 0 4 0 0

Ribometrix @Ribometrix

5 years ago

Today we announced a partnership with Genentech to discover and develop RNA-targeting small molecule therapeutic candidates against several targets. We will receive a $25M upfront payment and are eligible for potential milestone payments exceeding $1B. ribometrix.com/rbx-new/genent…

2 2 10 0 0

Ribometrix @Ribometrix

5 years ago

#Ribometrix is excited to add a new member to our leadership team, with the appointment of Barclay “Buck” Phillips as Chief Operating Officer and Chief Financial Officer: welcome, Buck! See the full Press Release here: ribometrix.com/rbx-new/buck-p…

0 2 0 0 0

Download Image

Ribometrix @Ribometrix

6 years ago

#Ribometrix strives to provide a fun culture and we enjoy participating in #teambuilding events. Most recently we volunteered with #HabitatForHumanity. Working together to #giveback truly embodies our #mission and #corevalues. #teamworkmakesthedreamwork #powertoolsarefun

0 1 10 0 0

Download Image

Ribometrix @Ribometrix

6 years ago

Exciting day, as we announce our partnership with Vertex Pharmaceuticals to discover and develop novel RNA-targeted small molecule therapeutic candidates for serious diseases. Full PR here: ribometrix.com/news_vertex.ht… @VertexPharma #RNA #RNA-targeted_small_molecules @TheRTP

3 6 16 0 0

Ribometrix @Ribometrix

6 years ago

Thrilled to announce $7.8 million in new funding from existing investors, the Dementia Discovery Fund and Illumina Ventures, and the appointment of Mike Clayman, M.D., as chairman of the board. ribometrix.com/news_A1-chair.… @DDF_VentureFund @illuminaventure #biotech #RNA @TheRTP

2 5 8 0 0

Ribometrix @Ribometrix

6 years ago

Welcome to John Reardon, our new CSO! He joins Don Hertzog, VP Drug Discovery, and Bill Janzen, VP Lead Discovery, who started in 2018. We are grateful to have these industry leaders join us in our endeavors to develop novel, RNA-targeting therapeutics. businesswire.com/news/home/2019…